TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Sanofi ( (SNY) ) is now available.
On November 25, 2025, Sanofi and Regeneron announced that the European Commission approved Dupixent (dupilumab) as the first targeted medicine in over a decade for treating moderate-to-severe chronic spontaneous urticaria (CSU) in the EU. This approval, based on phase 3 studies, marks a significant advancement for patients with CSU, providing a new treatment option that significantly reduces symptoms like itch and hives, which were previously inadequately controlled by standard antihistamines. The approval is expected to enhance Sanofi’s position in the immunology market and offer a new therapeutic option for the estimated 270,000 individuals in the EU suffering from CSU.
The most recent analyst rating on (SNY) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score reflects its strong earnings performance and attractive valuation, which are the most significant factors. The company’s financial stability and positive earnings call guidance further support the score, despite some technical analysis indicators suggesting a neutral trend.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. It focuses on various therapeutic areas, including immunology, oncology, rare diseases, and vaccines, with a significant presence in the European and global markets.
Average Trading Volume: 3,106,065
Technical Sentiment Signal: Strong Buy
Current Market Cap: $122.6B
For an in-depth examination of SNY stock, go to TipRanks’ Overview page.